Head and neck diseases
PRINCIPAL INVESTIGATORS
- Lorena Arribas Hortigüela
- Marc Oliva Bernal
CLINICAL RESEARCHERS
- Henry Lares Archer
- Miriam Hamdam Zavarce
- Julio Nogués Orpí
- Alicia Lozano Borbalas
- Francesc Cruellas Taischik
- Enric Cisa Lluis
- Laura Rodriguez Bel
- Mireia Melero Luque
- Antonio Mari Roig
- Josep Oriol Bermejo Segu
- Jordi Tornero Saltó
- Xavier González Compta
- Montserrat Gomà Gallego
- Silvia Cuscó Albors
- Mònica Cos Domingo
- María Plana Serrahima
- Marta Fulla Campi
- Alejandro Portillo Medina
- Aina Brunet García
- Marta Mesalles Ruíz
- Jesús Brenes Castro
- Carlos Arranz Obispo
- Anna Penella Prat
- Arnaud Morla
- Ricardo Bartel Arensburg
COLLABORATORS
- Aleix Rovira Casas
SCIENTIFIC SUPPORT
- Maria Sospedra Martinez
Cancer
Oncobell
Scientific production
21
PAPERS
Average IF: 6,28
13
LED PAPERS
Average IF: 4,22
1 PUBLICATION IN FIRST DECILE
5 PUBLICATIONS IN FIRST QUARTILE
10 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Spreaflco,A;Heirali,AA;Araujo,DV;Tan,TJ;Oliva,M;Schneeberger,PHH;Chen,B et al, First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial), Ann. Oncol., 2023;34(6):520-530, doi:10.1016/j.annonc.2023.02.011
- Mosteiro,M;Azuara,D;Villatoro,S;Alay,A;Gausachs,M;Varela,M;Baixeras,N et al, Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centre, ESMO Open, 2023;8(6):doi:10.1016/j.esmoop.2023.102197
- Hijazo Pechero,S;Alay,A;Cordero,D;Marin,R;Vilariño,N;Palmero,R;Brenes,J et al, Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications, Mol. Oncol., 2023;18(2):453-470, doi:10.1002/1878-0261.13550
- Naval Baudin,P;Pons Escoda,A;Camins,À;Arroyo,P;Viveros,M;Castell,J;Cos,M et al, Deeply 3D-T1-TFE hypointense voxels are characteristic of phase-rim lesions in multiple sclerosis., Eur. Radiol., 2023;34(2):1337-1345, doi:10.1007/s00330-023-09784-w,
- Majós,C;Pons Escoda,A;Naval,P;Guell,A;Lucas,A;Vidal,N;Cos,M et al, Proton MR spectroscopy shows improved performance to segregate high-grade astrocytoma subgroups when defined with the new 2021 World Health Organization classification of central nervous system tumors, Eur. Radiol., 2023;doi:10.1007/s00330-023-10138-9
Research highlights
PROJECTS
1 Granted competitive project
7 Ongoing competitive projects
14 Started clinical trials
34 Ongoing clinical trials
PUBLISHED WORKS
1 Clinical guideline
Selected projects
- 20ACL093. A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 OR PLACEBO IN COMBINATION WITH PEMBROLIZUMAB FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA. Budget: 236335,84. 2020- . PI: Plana Serrahima, María.
- 21ACL104. A RANDOMIZED, DOUBLE-BLIND PLACEBOCONTROLLED, PHASE 3 STUDY OF DEBIO 1143 IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY AND STANDARD FRACTIONATION INTENSITY-MODULATED RADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK, SUITABLE FOR DEFINITIVE CHEMORADIOTHERAPY (TRILYNX). Budget: 173660,76. 2021- . PI: Oliva Bernal, Marc.
- 2022-232-1. A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors. Seagen Inc. Budget: 171306,45. 2022- . PI: Oliva Bernal, Marc.
- 20ACL181. ESTUDIO DE FASE II, ABIERTO Y MULTICÉNTRICO DE AL101 EN PACIENTES CON CARCINOMA ADENOIDE QUÍSTICO (ACC) CON MUTACIONES ACTIVADORAS NOTCH. Budget: 97497. 2020- . PI: Oliva Bernal, Marc.
- PSJ22006. MoleculaR profiling and ImmunophEnotyping as preDictors of outcomE in non-metastatic SalIvary Gland carciNomas (REDESIGN). Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC). Budget: 80000. 2022-2024. PI: Oliva Bernal, Marc.